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Ethchlorvynol, a sedative-hypnotic drug used clinically since 1955, has recendy been the subject of
renewed interest primarily because of its chemical relationship to vinyl chloride. In our totigestational
studies, sperm-positive female rats were given a daily dose of ethchlorvynol dissolved in olive oil for 21
consecutive days. The dams were allowed to deliver and their offspring were observed for alterations in
development by monitoring a number of gross behavioral, histological and biochemical parameters at
newborn, weanling, puberty, adult and geriatric stages. Gross development appeared normal at time of
weaning; however, offspring of treated dams showed increased behavioral activity in addition to altera-
tions in a number of clinical chemistry parameters. The dose-response seen with most ofthe parameters
suggests that the changes are drug related. However, the clinical pathological significance has not been
ascertained.
There are numbers ofstudies tying vinyl chloride
exposure to angiosarcoma of the liver (1, 2), other
hepatic diseases (3, 4), chromosome aberrations (5),
alterations in spleen (6), and pulmonary function
(7), in addition to other pathological processes. All
of these observations place an urgency in studying
the mechanisms and far reaching consequences of
this and related compounds.
Ethchlorvynol is a chemical somewhat related to
vinyl chloride which has the capacity for altering
the function of many physiological processes, most
of which have been related to its CNS depressant
and skeletal muscle-relaxant effects. It was intro-
duced in 1955 as a clinically useful sedative-
hypnotic under the trade name Placidyl and has
competed quite effectively with the barbituric acid
derivatives in some areas. The physiological and
biochemical mechanisms by which these effects are
elicited have not been well defined. Only as re-
cently as the early 70's has there been any signifi-
cant attempt to understand it's disposition in either
animals or man.
Cummins et al. (8), in a clinical study showed that
the half-life of absorption for ethchlorvynol is ap-
proximately 0.3 hr. The decline in serum levels of
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the drug was found to be biphasic, suggesting that it
is stored, most likely in adipose tissue compart-
ments. On assuming a two-compartment model, the
rate constant of elimination was calculated to be
0.13 hr. Cummins also found that ethchlorvynol
was readily metabolized in the liver with only
0.025% of the dose excreted unchanged or as the
glucuronide.
Another disposition study, perhaps a little more
applicable to our work, was reported by Hume et
al. (9). These investigators showed that an oral dose
of ethchlorvynol given to pregnant dogs is rapidly
absorbed and readily distributed to the fetal circula-
tion in concentrations comparable to that found in
the maternal blood. Little if any delay was seen in
the drug reaching the fetal compartment.
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The various metabolites of ethchlorvynol have
notbeenidentified; howeverfrom thechemical struc-
tUre. one might think conjugation as the glucuronide
would be very likely. However, this metabolite has
been looked for- but has not been found. Other pos-
si'ble metabolites. such as other conjugates, a cy-
December 1977Table 1. Effect of totigestational exposure to ethchlorvynol on perinatal development.-
Ethchlorvynol Ethchlorvynol
Control 20 mg/kg 80 mg/kg
Maternal weight, g
Day 0 156 ±2 154 ± 2 154 ± 1
Day 7 161 ±2 162 ± 2 160 ± 2
Day 14 182 ±3 184 ± 3 178 ± 3
Day 21 226 ±3 230 ± 2 224 ±3
Day 22 171 ±3 175 ± 3 173 ±3
Sex ratio (M/F) 67/67 59/80 50/46
Litter size 9.6 ± 0.4 9.9 ± 0.5 9.2 ± 0.5
Weight ofpups, g
Birth 5.2 ± 0.1 5.2 ± 0.07 5.3 ± 0.1
I Week 11.0 ± 0.2 11.9 ± 0.2 11.2 ± 0.2
2 Week 20.1 ± 0.4 21.1 ± 0.3 20.6 ± 0.4
3 Week 29.2 ± 0.6 31.2 ± 0.5 30.2 ± 0.7
4 Week 56.0 ± 1 59.4 ± 0.9 58.7 ± 0.9
aValues are means ± S.E. for 10 to 14 litters.
clized five-membered ring, or products ofhydroxy-
ylation, reduction of unsaturated bonds, splitting
off of HCI or vinyl chloride, etc. need to be con-
sidered. However, none of these metabolites has
been identified.
Our studies on the transplacental pathology of
ethchlorvynol were initiatedbecause of: The lack of
information of transplacental effects on develop-
ment and the potential for long term pathology in
the offspring, the clinical usage in humans, the ab-
sence ofmetabolite information associated with the
possibility ofthe vinyl chloride moiety of ethchlor-
vynol reacting in a similar way to vinyl chloride in
the intact molecule or as a metabolite, and the oc-
currence of other unexplained complications as-
sociated with ethchlorvynol therapy.
Our studies, which are just beginning, are de-
signed to provide information on the effect of
ethchlorvynol on offspring of females subjected to
totigestational exposure. Sperm-positive female
rats were divided into three groups, and each group
was given a daily oral dose of olive oil (control) or
20 or 80 mg/kg ethchlorvynol dissolved in olive oil
for 21 days. The dams were allowed to deliver and
raise their offspring. The offspring were observed
for gross abnormalities and subjected to a number
of behavioral, developmental, histological, and
biochemical tests at various stages ofdevelopment.
The specific parameters monitored are shown in
Tables 1-7. The data presented in the tables are for
the most part as the means + S.E. Control-treated
comparisons were made using Student's t; the level
of significance is p < 0.05.
Table 1 presents maternal and newborn statistics.
No significant differences were seen between con-
trol and treated groups, however treated animals
tend to be slightly heavier by 3 to 4 weeks.
Table 2 shows the age of the animals at time of
eye opening and onset of puberty in females as de-
termined by vaginal opening. By day 56 all groups
showed 100% vaginal opening.
Table 2. Effect oftotigestational exposure to ethchlorvynol on eye
opening and vaginal opening.
Proportion of total offspring responding
Ethchlorvynol Ethchlorvynol
Control 20 mg/kg 80 mg/kg
Eye openinga
1S days 0 0 0
16 days 12 8 13
17 days 35 39 36
18 days 75 79 73
19 days 100 100 100
Vaginal openinga
31 days 0 0 0
39 days 29 33 39
46 days 76 67 82
49 days 79 72 89
53 days 87 93 96
aDays of postnatal life.
Table 3 shows no difference in control versus
treated groups in the three physiological parameters
studied. However, treatment causes a trend toward
decreased time for righting, suggesting increased
activity in the offspring.
The results of behavioral tests are seen in Table
4, which shows a dose-response increased ex-
ploratory activity in both male and female weanling
animals. Treated male animals tend to require less
time to run the food maze with fewer mistakes than
do the controls; however a dose response was not
seen. Treated females were practically identical to
the control females.
Clinical chemistry and hematological observa-
tions in weanling animals are presented in Tables 5
and 6. Several parameters-blood glucose,
chloride, albumin, total bilirubin, SGOT, acid-base
balance, and creatine phosphokinase-were all
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and muscle strength.
Ethchlorvynol Ethchlorvynol
Control 20 mg/kg 80 mg/kg
Righting reflex time, sec0 1.6 ± 0.2 1.2 ± 0.2 1.2 ± 0.2
Temperature regulation
7 days, secb 146 ±7 131 ±5 150 ± 14
14 days,°C/5 minc 0.96 ± 0.2 1.22 ± 0.2 0.86 ± 0.2
Inclined screen, sec'
7 days 61.2 ±6 59.0 ±5 63.0 10
14 days 180 ±18 168 ±24 216 ±24
aTime for the animals to turn from back to feet; values are means + S.E.
bLength of time needed to lose 1°C of body temperature.
cBody temperature change in 5 min.
dLength of time animals would adhere to a screen inclined at450 angle (7 days) or at a 750 angle (14 days).
Table 4. Effect of totigestational exposure to ethchlorvynol on behavior0
Ethchlorvynol Ethchlorvynol
Control 20 mg/kg 80 mg/kg
Males Females Males Females Males Females
Openfield testb 33 ± 2 38 ± 4 41 ± 3 44 ±2 44 ±3 47 ± 2
Food maze, 24 hrc
Time, sec 137 ± 43 58 ± 8 63 ± 13 68 ±28 105 ±28 57 ± 8
Mistakes 12 ±3.0 7 ± 1.3 4.6 ± 1 4.2 1 7.9 2 6 ± I
Food maze, 48 hrc
Time, sec 41 ±22 28 ± 7 23 ± 7 38 ±5 23 ±5 33 ± 10
Mistakes 4.6 ± 1.3 3.5 ± 0.1 2.5 ± 8 4.1 ± 1 3 ± 0.2 4.8 ± 1.4
aValues are means + S.E. for 8 animals at 4 to 5 weeks of age.
'The number of squares visited during 60 sec in the testing device.
cThe length oftime to run the maze following 24 and 48 hr food deprivation and the numberofmistakes made during the
run.
Table S. Effect of totigestational exposure to ethchlorvynol on dinical chemistry.a
Glucose, mg/dl
BUN, mg/dl
Creatinine, mg/dl
Sodium, meqll.
Potassium, meq/1.
Chloride, meq/l.
Carbon dioxide, meq/l.
Uric acid, mg/dl
Cholesterol, mg/dl
Triglyceride, mg/dl
Albumin, g/dl
Total protein, g/dl
Calcium, mg/dl
Phosphorus, mg/dl
Total bilirubin, mg/dl
SGOT u/l
SGPT u/l
(Na-[Cl + C02]) (Balance)
Alkaline phosphatase, u/i
Creatine phosphokinase, ul
aValues are mean ± S.E. for 10 weanling animals.
bStatistically different from control.
Control
151 ±1
16 ±1
0.5 ± 0.02
142 +1
5.3 ± 0.2
105 ± 0.5
28 ±1
2.6 ± 0.2
101 ±3
112 ±8
4.8 ± 0.05
4.8 ± 0.05
10.8 ±2
9.2 ± 0.2
0.08 ± 0.02
156 10
56 ±4
9.5 ± 0.3
902 30
933 ± 103
Ethchlorvynol
20 mg/kg
150 ± 2.6
14 ±0.6
0.45 ± 0.02
141 ± 0.2
5.3 ± 0.3
106 ±0.2
26 ±1.2
2.5 ± 0.2
96 ±1.8
98 ±2.2
4.7 ± 0.06
4.8 ± 0.08
10.4 ± 0.03
8.9 ± 0.16
0.06 ± 0.02
129 ± 5
52 ± 4
8.8 ± 0.4
835 ± 80
611 ± 55
Ethchlorvynol
80 mg/kg
172 + 6b
15 ±1.5
0.425 ± 0.05
140 ± 0.25
5.2 ± 0.2
108 ± OP.b
26 t 1
2.0 ± 0.1
93 ± 2.5
78 ± 12
4.5 ± 0.05b
4.6 ± 0.05
10.4 + 0.1
8.6 ± 0.1
0.01 t 0b
117 +5b
47 t 1.5
6.0
t lb
848 ± 88
559 ± 56b1
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Ethchlorvynol Ethchlorvynol
Control 20 mg/kg 80 mg/kg
MCHC, % 32.4 ± 0.4 31.5 ± 0.8 32.5 ± 0.5
MCH, pg 20.8 ± 0.3 20.8 ± 0.7 20.9 ± 0.4
MCV, ,gm3 64.8 ± 1.2 66.2 ± 0.8 65.0 ± 0.8
PCV, % 35.1 ± 0.5 36.0 ± 0.4 34.8 ± 0.9
Hb, g/dl 11.4 ± 0.16 11.3 ± 0.3 11.3 ± 0.4
RBC x 106 5.46 ± 0.06 4.47 ± 1.1 5.42 ± 0.11
WBC x 103 2.8 ± 0.1 2.7 ± 0.16 3.2 ± 0.3
Differential
Seg, % 8.6 ± 0.6 6.4 ± 1.2 6.2 ± 1
Band, % 5.2 ± 2 4.0 ± 1.2 3.8 ± 1.5
Lymph, % 82 ±2.4 83 ± 2.8 87 ± 1.3
Mono, % 2.8 ±1 5.2 ± 1.6 3.5 ± 0.5
Eosin % 1.2 ±0.6 1.2 ± 0.6 1.0 ± 0.6
aValues are the means ± S.E. for 10 weanling animals.
statistically different from those at the controls. A
number of the parameters showed a dose-response
relationship which supports the idea of a drug-
related effect. However, the biological significance
is not obvious at this point in our experiments. A
repetition ofthese results in another group ofwean-
ling animals or in animals ofpuberty age would add
to the significance of these results.
No changes were seen in the hematological
parameters. In animals autopsied at 5 weeks of age
the 80 mg/kg treatment group was significantly
heavier than the control, while the 20 mg/kg group
was intermediate (Table 7). It is interesting to note
that the mean weightofthe brain, pituitary, thyroid,
liver, epididymis, and uterus was smaller in the 80
mg/kg-treated animals than in the controls, in spite
of the increased body weight.
As pointed out earlier, these data are preliminary
and need to be repeated in another group of wean-
!ing animals or supported by data from puberty-
aged animals. Datajust obtained in puberty animals
tend to confirm the idea that totigestational treat-
ment with ethchlorvynol causes increased activity
in the offspring and further suggest that the in-
creased activity may be of a somewhat random na-
ture.
Table 7. Effect of totigestational exposure to ethchlorvynol on organ weight.'
Ethchlorvynol Ethchlorvynol
Organ Control 20 mg/kg 80 mg/kg
Whole body, g 56.2 ± 1.1 60.7 ± 1.8 61.6 ± 1.3b
Brain, g 1.56 ± 0.06 1.58 ± 0.04 1.50 ± 0.02
Pituitary, mg 4.1 ± 0.6 3.9 ± 0.4 2.8 ± 0.1
Thyroid, mg 14.6 ± 1.7 12.9 ± 1.0 13 ± 1.1
Lung (R), g 0.381 ± 0.03 0.386 ± 0.01 0.363 ± 0.017
Lung (L), g 0.208 ± 0.01 0.222 ± 0.01 0.225 ± 0.007
Heart, g 0.229 ± 0.01 0.241 ± 0.01 0.240 ± 0.007
Thymus, mg 206 ± 13 213 ±11 220 ± 9
Kidney (R), g 0.301 ± 0.02 0.303 ± 0.01 0.299 ± 0.013
Kidney (L), g 0.288 ± 0.02 0.293 ± 0.01 0.292 ± 0.015
Adrenal (R), mg 7.9 ± 0.4 9.8 ±1 7.9 ±0.4
Adrenal (L), mg 9.2 ± 0.7 11.0 ± 0.5 9.3 ± 0.5
Liver, g 2.55 ± 0.1 2.57 ± 0.1 2.50 ± 0.13
Spleen, g 0.181 ± 0.01 0.188 ± 0.01 0.192 ± 0.01
Pancreas, g 0.245 ± 0.01 0.226 ± 0.01 0.253 ± 0.02
Prostate, mg 73 ± 8 82 ± 8 86 ±3
Testicles, g 0.337 ± 0.015 0.347 ± 0.01 0.378 ± 0.03
Epididymis, mg 61 ± 10 45 ± 5 46 ± 4
Ovaries, mg 26 ± 2 26 ± 3 27 ± 5
Uterus, mg 39 ± 12 38 ± 5 29 ± 7
aValues are means ± S.E. Animals were 5 weeks old.
bStatistically different from control.
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